Alnylam [ALNY] vs Vertex [VRTX] Detailed Stock Comparison

Alnylam Pharmaceuticals Inc.

NASDAQ
Loading...

Vertex Pharmaceuticals Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Alnylam Pharmaceuticals Inc. wins in 1 metrics, Vertex Pharmaceuticals Inc. wins in 19 metrics, with 0 ties. Vertex Pharmaceuticals Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Alnylam Pharmaceuticals Inc. Vertex Pharmaceuticals Inc. Better
P/E Ratio (TTM) 132.73 28.40 Vertex Pharmaceuticals Inc.
Price-to-Book Ratio 52.09 5.92 Vertex Pharmaceuticals Inc.
Debt-to-Equity Ratio 376.19 10.91 Vertex Pharmaceuticals Inc.
PEG Ratio 22.00 0.88 Vertex Pharmaceuticals Inc.
EV/EBITDA 74.03 21.78 Vertex Pharmaceuticals Inc.
Profit Margin (TTM) 8.45% 32.94% Vertex Pharmaceuticals Inc.
Operating Margin (TTM) 12.01% 39.60% Vertex Pharmaceuticals Inc.
EBITDA Margin (TTM) 12.01% 39.60% Vertex Pharmaceuticals Inc.
Return on Equity 73.28% 22.54% Alnylam Pharmaceuticals Inc.
Return on Assets (TTM) 6.81% 12.16% Vertex Pharmaceuticals Inc.
Free Cash Flow (TTM) $465.38M $3.19B Vertex Pharmaceuticals Inc.
1-Year Return -8.16% -2.31% Vertex Pharmaceuticals Inc.
Price-to-Sales Ratio (TTM) 11.16 9.22 Vertex Pharmaceuticals Inc.
Enterprise Value $41.25B $105.96B Vertex Pharmaceuticals Inc.
EV/Revenue Ratio 11.11 8.83 Vertex Pharmaceuticals Inc.
Gross Profit Margin (TTM) 75.60% 85.39% Vertex Pharmaceuticals Inc.
Revenue per Share (TTM) $28 $47 Vertex Pharmaceuticals Inc.
Earnings per Share (Diluted) $2.34 $15.32 Vertex Pharmaceuticals Inc.
Beta (Stock Volatility) 0.38 0.37 Vertex Pharmaceuticals Inc.
Short % of Float 5.05% 1.78% Vertex Pharmaceuticals Inc.

Alnylam Pharmaceuticals Inc. vs Vertex Pharmaceuticals Inc. Stock Performance Analysis

Loading Price Chart...

ALNY
VRTX

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Alnylam Pharmaceuticals Inc.1.75%-1.49%0.29%-9.76%-26.49%-28.08%
Vertex Pharmaceuticals Inc.1.24%1.69%3.09%-3.36%-1.15%-0.37%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Alnylam Pharmaceuticals Inc.-8.16%40.32%59.90%405.36%3,032.34%1,907.45%
Vertex Pharmaceuticals Inc.-2.31%27.89%136.85%413.01%888.51%1,245.83%

Performance & Financial Health Analysis: Alnylam Pharmaceuticals Inc. vs Vertex Pharmaceuticals Inc.

MetricALNYVRTX
Market Information
Market Cap i$41.87B$109.45B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i1,075,3691,057,061
90 Day Avg. Volume i1,141,7561,272,097
Last Close$287.80$450.46
52 Week Range$281.36 - $495.55$362.50 - $507.92
% from 52W High-41.92%-11.31%
All-Time High$495.55 (Oct 20, 2025)$519.88 (Nov 04, 2024)
% from All-Time High-41.92%-13.35%
Growth Metrics
Quarterly Revenue Growth0.85%0.10%
Quarterly Earnings Growth0.85%0.31%
Financial Health
Profit Margin (TTM) i0.08%0.33%
Operating Margin (TTM) i0.12%0.40%
Return on Equity (TTM) i0.73%0.23%
Debt to Equity (MRQ) i376.1910.91
Cash & Liquidity
Book Value per Share (MRQ)$5.96$73.49
Cash per Share (MRQ)$21.93$26.01
Operating Cash Flow (TTM) i$524.08M$3.63B
Levered Free Cash Flow (TTM) i$128.79M$2.57B
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Alnylam Pharmaceuticals Inc. vs Vertex Pharmaceuticals Inc.

MetricALNY (Apr 24, 2026)VRTX (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i132.7328.40
Forward P/E i22.0019.95
PEG Ratio i22.000.88
Price to Sales (TTM) i11.169.22
Price to Book (MRQ) i52.095.92
Market Capitalization
Market Capitalization i$41.87B$109.45B
Enterprise Value i$41.25B$105.96B
Enterprise Value Metrics
Enterprise to Revenue i11.118.83
Enterprise to EBITDA i74.0321.78
Risk & Other Metrics
Beta i0.380.37
Book Value per Share (MRQ) i$5.96$73.49

Financial Statements Comparison: Alnylam Pharmaceuticals Inc. vs Vertex Pharmaceuticals Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricALNY (2025)VRTX (2025)
Revenue/Sales i3.71B12.00B
Cost of Goods Sold i681.87M1.65B
COGS % of Revenue i18.4%13.8%
Gross Profit i3.03B10.35B
Gross Margin i81.6%86.2%
Research & Development i1.32B4.04B
Operating Income (EBIT) i501.58M4.55B
Operating Margin i13.5%37.9%
EBITDA i676.22M5.25B
EBITDA Margin i18.2%43.7%
Pre-Tax Income i323.15M4.64B
Pre-Tax Income % of Revenue i8.7%38.7%
Income Tax i9.41M690.00M
Income Tax % of Revenue i0.3%5.7%
Net Income (Profit) i313.75M3.95B
Profit Margin i8.4%32.9%

Balance Sheet & Liquidity Metrics

MetricALNY (2025)VRTX (2025)
Cash & Equivalents i1.66B5.08B
Total Current Assets i4.05B11.20B
Total Current Assets % of Revenue i109.1%93.3%
Total Current Liabilities i1.47B3.86B
Total Current Liabilities % of Revenue i39.5%32.2%
Long-Term Debt i1.23B1.95B
Long-Term Debt % of Revenue i33.2%16.3%
Total Shareholders Equity i789.18M18.67B
Retained Earnings i-6.70B13.56B
Retained Earnings % of Revenue i-180.5%113.0%
Property, Plant & Equipment i384.79M1.56B

Cash Flow Statement Comparison

MetricALNY (2025)VRTX (2025)
Operating Cash Flow i639.50M3.77B
Operating Cash Flow % of Revenue i17.2%31.4%
Capital Expenditures i-58.70M-437.60M
Free Cash Flow i465.38M3.19B
FCF Margin i12.5%26.6%
Debt Repayment i-1.19B-5.40M
Common Stock Repurchase iN/A-2.39B

Short Interest & Institutional Ownership Analysis

MetricALNYVRTX
Shares Short i5.06M4.02M
Short Ratio i4.492.80
Short % of Float i5.05%1.78%
Shares Outstanding i132.38M253.99M
Float Shares i132.07M253.24M
% Held by Insiders i0.19%0.21%
% Held by Institutions i101.05%97.60%
% Held by Public i-1.24%2.19%

Dividend Analysis & Yield Comparison: Alnylam Pharmaceuticals Inc. vs Vertex Pharmaceuticals Inc.

MetricALNYVRTX
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A